Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications.

Abstract excerpt

Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers, with a minimal difference between its incidence rate and mortality rate. Advances in oncology over the past several decades have dramatically improved the overall survival of patients with multiple cancers due to the implementation of new techniques in early diagnosis, therapeutic drugs, and personalized therapy. However, pancreatic...

Topics

Join the communities discussing this publication.

• Carcinoma, Pancreatic Ductal
• Clinical Trials as Topic
• Molecular Targeted Therapy
• Oncogenes
• Pancreatic Neoplasms